{
    "clinical_study": {
        "@rank": "75749", 
        "brief_summary": {
            "textblock": "To determine the maximum tolerated dose (MTD) of hypericin, to define the types of\n      toxicities that may be observed, and to determine what doses of the drug are associated with\n      improvements in virological and immunological surrogate markers of HIV infection. To\n      determine the bioavailability of synthetic hypericin given in 2 percent benzyl alcohol\n      solution.\n\n      Hypericin is unlike other drugs presently being used to treat AIDS patients. Hypericin shows\n      anti-HIV activity in test tube experiments."
        }, 
        "brief_title": "A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes", 
        "completion_date": {
            "#text": "October 1994", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Hypericin is unlike other drugs presently being used to treat AIDS patients. Hypericin shows\n      anti-HIV activity in test tube experiments.\n\n      Each group of eight patients receives a given dose of hypericin by intravenous infusion.\n      Doses are given three times per week for 8 weeks. When all eight patients at a dose level\n      have been entered and four of the eight patients have completed 3 weeks of therapy without\n      evidence of dose-limiting toxicity, additional patients may begin to receive drug at the\n      next dose level. Concurrently, six patients wll participate in an oral-dosing\n      bioavailability study. NOTE: The initial study was stopped secondary to an MTD being\n      reached."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Prophylaxis for Pneumocystis carinii pneumonia (required for patients with CD4+ <\n             200).\n\n          -  Symptomatic treatment with analgesics, antihistamines, antiemetics, antidiarrheal\n             agents, or other supportive therapy.\n\n          -  Short courses (< 10 days) with ketoconazole or fluconazole for oral candidiasis or\n             acyclovir for herpes lesions.\n\n          -  Topical medications such as clotrimazole troches or nystatin suspensions.\n\n        Concurrent Treatment:\n\n        Allowed:\n\n          -  Blood transfusions.\n\n        Patients must have HIV infection with CD+4 lymphocyte count of < 300 cells/mm3.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded.\n\n          -  Kaposi's sarcoma requiring systemic therapy.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Continued use of opiates or drugs known to induce photosensitivity.\n\n        Patients with the following are excluded:\n\n          -  Active or chronic opportunistic infection at time of study entry that required\n             curative or suppressive therapy.\n\n          -  Significant liver disease, orthostatic hypotension, cardiac disease, seizure\n             disorder, lymphoma, hypotension.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Zidovudine (AZT), dideoxyinosine (ddI), dideoxycytidine (ddC), interferon, other\n             antiretroviral agents or immunomodulating drugs within 1 month prior to study entry.\n             Ribavirin within 3 months of study entry.\n\n          -  Ganciclovir (DHPG), antimycobacterial drugs, MAO inhibitors, hypertension-inducing,\n             nephrotoxic, or hepatotoxic drugs within 14 days of entry.\n\n          -  Cytotoxic chemotherapy within 1 month prior to study entry.\n\n        Active substance abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "32", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000645", 
            "org_study_id": "ACTG 150", 
            "secondary_id": "11125"
        }, 
        "intervention": {
            "intervention_name": "Hypericin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Hypericin"
        }, 
        "keyword": [
            "Drug Evaluation", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Antiviral Agents"
        ], 
        "lastchanged_date": "March 29, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Deaconess - East Campus A0102 CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "University of Minnesota, ACTU"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "NY Univ. HIV/AIDS CRS"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes", 
        "overall_official": {
            "last_name": "Valentine FT", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Unspecified"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "citation": "Gulick R, Lui H, Anderson R, Kollias N, Hussey S, Crumpacker C. Human hypericism: a photosensitivity reaction to hypericin (St. John's Wort). Int Conf AIDS. 1992 Jul 19-24;8(2):B90 (abstract no PoB 3018)"
            }, 
            {
                "citation": "Mcauliffe V, et al. A phase I dose escalation study of synthetic hypericin in HIV infected patients (ACTG 150). Natl Conf Hum Retroviruses Relat Infect (1st). 1993 Dec 12-16:159"
            }, 
            {
                "PMID": "10075619", 
                "citation": "Gulick RM, McAuliffe V, Holden-Wiltse J, Crumpacker C, Liebes L, Stein DS, Meehan P, Hussey S, Forcht J, Valentine FT. Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258. Ann Intern Med. 1999 Mar 16;130(6):510-4."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000645"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "collaborator": {
                "agency": "VIMRx Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2012"
    }, 
    "geocoordinates": {
        "Beth Israel Deaconess - East Campus A0102 CRS": "42.358 -71.06", 
        "NY Univ. HIV/AIDS CRS": "40.714 -74.006", 
        "University of Minnesota, ACTU": "44.98 -93.264"
    }
}